Completed PHASE3 INTERVENTIONAL NCT00050947

Pediatric Epilepsy Study

A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures.

Sponsor: Novartis Pharmaceuticals

Conditions Epilepsy

Interventions oxcarbazepine

Updated 7 times since 2017 Last updated: Nov 22, 2011 Started: Jul 31, 2002 Primary completion: Feb 29, 2004 Completion: Feb 29, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Epilepsy, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Ann Arbor, United States , Atlanta, United States , Birmingham, United States , Buffalo, United States , Chesterfields, United States , Cincinnati, United States , Cleveland, United States , Denver, United States , Duluth, United States and 20 more locations